ENGLEWOOD CLIFFS, N.J, July 12, 2022 (GLOBE NEWSWIRE) — Silo Pharma, IncĀ . (OTCQB: SILO), a development-stage biopharmaceutical company today announces that its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method.
Eric Weisblum, CEO of Silo Pharma commented āThe successful results of our study show that the subcutaneous route of liposomal administration is well-suited for use in targeted drug delivery of anti-arthritic agents. We suggest that this drug delivery approach would not only enhance efficacy but also reduce systemic toxicity.ā
In our previous work, ART-1-Cy7-liposomes injected i.v. demostrated homing to arthritic joints and 4 hours was an optimal time point for high fluorescence intensity in the hind paws. The results of this new study show that the time kinetics and quantitative aspects of liposomes administered subcutaneous were not much different from that of liposomes injected i.v. In fact, despite some initial delay, the signal strength showed a trend towards a higher level in subcutaneous than in i.v.
About Silo PharmaĀ
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinsonās, and other rare neurological disorders. Siloās mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visitĀ www.silopharma.com
Safe Harbor and Forward-Looking StatementsĀ
This news release contains “forward-looking statements” within the meaning of the āsafe harborā provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words ācouldā, ābelieveā, āanticipateā, āintendā, āestimateā, āexpectā, āmayā, ācontinueā, āpredictā, āpotentialā, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (āSiloā or āthe Companyā) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Companyās technology platforms, retaining and expanding the Companyās customer base, fluctuations in consumer spending on the Companyās products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.
Investor Relations Contact:Ā
Hayden IRĀ
Brett MaasĀ
646-536-7331Ā
Email: brett@haydenir.com